IRIS
GIANNINI, EDOARDO GIOVANNI BATTISTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 38.877
NA - Nord America 5.122
AS - Asia 4.879
Continente sconosciuto - Info sul continente non disponibili 1.283
SA - Sud America 412
AF - Africa 77
OC - Oceania 9
Totale 50.659
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 37.949
US - Stati Uniti d'America 4.743
SG - Singapore 1.864
CN - Cina 1.155
VN - Vietnam 728
BD - Bangladesh 640
FR - Francia 393
BR - Brasile 250
CA - Canada 165
HK - Hong Kong 152
FI - Finlandia 126
DE - Germania 102
GB - Regno Unito 79
MX - Messico 76
AR - Argentina 72
JP - Giappone 60
IN - India 49
ID - Indonesia 37
JM - Giamaica 35
PL - Polonia 35
CH - Svizzera 30
NL - Olanda 27
IQ - Iraq 26
EC - Ecuador 25
CR - Costa Rica 24
ES - Italia 24
RU - Federazione Russa 19
CO - Colombia 18
SE - Svezia 18
NI - Nicaragua 17
CL - Cile 15
UZ - Uzbekistan 15
IE - Irlanda 14
UA - Ucraina 14
ZA - Sudafrica 14
MA - Marocco 13
SA - Arabia Saudita 13
VE - Venezuela 13
AE - Emirati Arabi Uniti 12
HN - Honduras 12
PH - Filippine 12
PK - Pakistan 12
JO - Giordania 11
NP - Nepal 11
AZ - Azerbaigian 10
TR - Turchia 10
GT - Guatemala 9
KR - Corea 9
SV - El Salvador 9
TT - Trinidad e Tobago 9
AU - Australia 8
DZ - Algeria 8
KE - Kenya 8
TW - Taiwan 8
TH - Thailandia 7
UY - Uruguay 7
ET - Etiopia 6
MY - Malesia 6
PY - Paraguay 6
TN - Tunisia 6
AL - Albania 5
AT - Austria 5
CZ - Repubblica Ceca 5
KZ - Kazakistan 5
PE - Perù 5
PT - Portogallo 5
BE - Belgio 4
IL - Israele 4
LB - Libano 4
OM - Oman 4
PR - Porto Rico 4
RS - Serbia 4
XK - ???statistics.table.value.countryCode.XK??? 4
BB - Barbados 3
CY - Cipro 3
DO - Repubblica Dominicana 3
EG - Egitto 3
SK - Slovacchia (Repubblica Slovacca) 3
BG - Bulgaria 2
BY - Bielorussia 2
BZ - Belize 2
CD - Congo 2
CG - Congo 2
CI - Costa d'Avorio 2
GA - Gabon 2
GP - Guadalupe 2
HU - Ungheria 2
KH - Cambogia 2
LT - Lituania 2
LV - Lettonia 2
NG - Nigeria 2
PA - Panama 2
PS - Palestinian Territory 2
SN - Senegal 2
BA - Bosnia-Erzegovina 1
BM - Bermuda 1
BO - Bolivia 1
CU - Cuba 1
CW - ???statistics.table.value.countryCode.CW??? 1
DJ - Gibuti 1
Totale 49.356
Salva come PNG Salva come JPEG
Città #
Genova 21.585
Genoa 9.979
Rapallo 3.046
Vado Ligure 2.542
San Jose 954
Singapore 832
Ashburn 574
Lauterbourg 358
New York 269
Council Bluffs 243
Ho Chi Minh City 204
Beijing 185
Hanoi 174
Hong Kong 145
Los Angeles 145
Santa Clara 131
Dallas 110
Helsinki 102
Milan 86
Frankfurt am Main 81
Chicago 71
Bordighera 70
Rome 70
Boardman 64
Tokyo 56
Buffalo 53
Orem 49
Mexico City 46
Montreal 40
Phoenix 40
San Francisco 37
Atlanta 35
Warsaw 34
Brooklyn 33
Turin 33
Naples 32
Denver 31
Houston 29
Da Nang 28
Toronto 28
Haiphong 27
São Paulo 27
Zurich 26
Seattle 25
Lappeenranta 23
St Louis 23
Tianjin 23
Bologna 20
Kingston 20
San José 20
Philadelphia 19
Florence 18
Jacksonville 18
Miami 18
Stockholm 18
Amsterdam 17
Charlotte 17
Des Moines 17
Brescia 16
Boston 15
Columbus 15
Dublin 15
Figino 15
Palermo 15
Washington 15
Shanghai 14
Cardiff 13
Chennai 13
Managua 13
Tampa 13
Tashkent 13
Guangzhou 12
Hải Dương 12
Manchester 12
Memphis 12
Newark 12
Vancouver 12
Amman 11
Hamilton 11
Las Vegas 11
London 11
Baghdad 10
Bari 10
City of London 10
Dubai 10
Guayaquil 10
Madrid 10
Poplar 10
The Bronx 10
Baku 9
Detroit 9
Mumbai 9
Pittsburgh 9
Queens 9
Quảng Ngãi 9
San Salvador 9
Anchorage 8
Ancona 8
Augusta 8
Biên Hòa 8
Totale 43.476
Salva come PNG Salva come JPEG
Nome #
EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis 755
Hepatobiliary and Pancreatic: A rare cause of portal hypertension. 245
5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for “best evidence”? 226
A new assay for hepatitis C virus (HCV) core antigen detection: an alternative to nucleic acid technologies in positive or indeterminate anti-HCV subjects? 225
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. 223
13C -Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. 217
Positive PET in a patient with esophageal leiomyoma. 216
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index 215
Long-Term Follow-Up Study of Liver-Related Outcome After Bilio-Pancreatic Diversion in Patients with Initial, Significant Liver Damage 215
Epidemiological and clinical features of hepatitis delta in HBsAg-positive patients by HIV status. 210
Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C 208
13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease 207
Personalized treatment of patients with very early hepatocellular carcinoma 207
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice 203
Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis 198
Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: a validation study based on follow-up 197
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 197
A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. 197
A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice 195
High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease 193
Breath tests to assess alcoholic liver disease. 191
A study of 4-and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication 191
Acquired Hepatocerebral Degeneration in the Absence of Portosystemic Shunting 191
. Liver iron accumulation in chronic hepatittis C patients without HFE mutations: relationships with histological damage, viral load and genotype, and alpha glutathione S-transferase levels. 188
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 185
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy 181
A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients 181
Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. 180
Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis 180
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. 177
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 177
Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease 176
Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria 176
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. 175
Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases 173
IL28B rs12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin. 172
Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis? 171
Starry Liver: An Unexpected Diagnosis 171
Improvement in Waldenstrom’s macroglobulinemia after successful treatment of HCV with direct-acting antivirals 171
Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn’s disease. 170
A Nodule, is a Nodule, is a Nodule: May Alpha-fetoprotein Make the Difference? 170
A new approach to the use of alfa-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. 169
Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study 169
Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma 168
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals 168
A Liver Index and its Relationship to Indices of HCC Aggressiveness 168
Adalimumab trough levels and response to biological treatment in patients with Inflammatory Bowel Disease: a useful cut-off In clinical practice. 167
Curative therapies are superior to standard of care(transarterial chemoembolization)for intermediate stage hepatocellular carcinoma 167
Pattern of macrovascular invasion in hepatocellular carcinoma 166
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens 165
Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: the perfect storm 165
The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin 165
12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies. 165
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: characteristics and outcome of antiviral therapy. 164
External Validation of the Platelet Count/Spleen Diameter Ratio for the Diagnosis of Esophageal Varices in Hepatitis C Virus-Related Cirrhosis 164
Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma 164
High ascitic fluid leptin levels in patients with decompensated liver cirrhosis and sterile ascites: Relationship with TNF-alpha levels 163
Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. 162
PRO: Cirrhotic patients with small esophageal varices should undergo primary prophylaxis 162
Hepatocellular carcinoma in patients with cryptogenic cirrhosis 162
A summary of the 6th international conference on coagulation in liver disease: Discussion, debate, deliberations 162
An independent validation of the mortality score for the short-term prognostic prediction in patients with chronic hepatitis C virus infection and advanced liver disease 161
Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. 161
Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations 161
Effects of reduced glutathione and n-acetylcysteine on lidocaine metabolism in cimetidine treated rats 160
Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease 160
Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients 160
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 159
Platelet dysfunction: status of thrombopoietin in thrombocytopenia associated with chronic liver failure 158
Chronic hepatitis C in different populations: similar patterns of alanine aminotransferase alteration characterize similar clinical subgroups. 158
Optimal management of constipation associated with irritable bowel syndrome. 158
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 158
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 158
Is there a role for multiple quantitative liver function tests? 157
Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients. 157
Blessed are those who have not seen and yet have believed 157
MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study 157
Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. 157
Leptin in nonalcoholic steatohepatitis: is it one of the "hits"? 157
13CO2 excretion in breath of normal subjects and cirrhotic patients after 13C-Aminopyrine oral load. Comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis 156
Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. 156
A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease 156
Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. 155
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. 154
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. 152
Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden 151
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia 151
Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems 150
Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C 150
Persistently normal aminotransferase in chronic hepatitis C virus infection: is it time to redefine parameters of "normality"? 149
Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients 149
Alpha-fetoprotein in hepatocellular carcinoma surveillance: wake not the dead. 148
Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study. 148
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 148
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 148
Comparison of the Safety and Efficacy of Ustekinumab and Vedolizumab in Patients with Crohn’s Disease: A Systematic Review and Meta-Analysis of Propensity Score Matched Cohort Studies 147
An HCC Aggressiveness Index and Blood GTP, Bilirubin and Platelet Levels 147
Influence of 1-week helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test 146
Liver enzyme alteration: a guide for clinicians 146
Hepatocellular carcinoma in patients without cirrhosis in Italy. 145
Totale 17.807
Salva come PNG Salva come JPEG
Categoria #
all - tutte 171.198
article - articoli 169.026
book - libri 0
conference - conferenze 329
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.843
Totale 342.396
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.035 174 266 310 354 126 252 239 997 267 360 209 481
2022/20233.705 384 228 37 284 603 614 34 361 685 21 391 63
2023/20241.986 95 277 40 238 171 229 128 120 116 74 153 345
2024/20256.539 232 483 229 382 868 666 586 1.091 262 288 629 823
2025/202613.965 1.253 430 1.147 1.204 1.455 1.290 1.937 599 980 1.536 950 1.184
2026/20272.125 2.125 0 0 0 0 0 0 0 0 0 0 0
Totale 50.659